Carlyle Group Inc., the alternative asset manager overseeing $221 billion, is buying a majority stake in clinical data company TriNetX Inc.

Equity capital for the investment came from the $18.5 billion private equity fund, Carlyle Partners VII, the company said Monday, declining to comment on deal terms.

Closely held TriNetX has built a global network of research hospitals and academic institutions, biotechnology and drug companies, contract research organizations and other specialty data partners. Carlyle’s investment will help the company, founded in 2013, bring more technologies such as artificial intelligence and machine learning to researchers, according to Gadi Lachman, chief executive officer of Cambridge, Massachusetts-based TriNetX.

TriNetX is positioned to “have an impact on human health and reduce the time and costs involved in bringing new drugs to market,” Joe Bress, a principal specializing in health care at Washington-based Carlyle, said in an interview.

The deal adds to Carlyle’s growth investments in the health-care industry. The firm said earlier this month it led a $175 million round for Grand Rounds. Carlyle also backed 1Life Healthcare Inc., the primary-care clinic chain that went public in January. Other deals have focused more broadly on technology. The firm backed ZoomInfo Technologies Inc., which went public in June, and completed the sale of automation provider Eggplant Software to Keysight Technologies Inc. later that month.

Source: Bloomberg

Can’t stop reading? Read more